Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Discussing Use of Data from “Specified Clinical Research” in Application Dossiers, Will Issue Preliminary Conclusions by March
August 29, 2018
-
BUSINESS Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
-
BUSINESS Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
-
REGULATORY Japan Eyes State Funds to Boost Sakigake Review Staffers: FY2019 Budget Request
August 27, 2018
-
REGULATORY MHLW to Expand MID-NET and Coordinate with Other Databases and Registries to Improve Safety Measures: Official
August 27, 2018
-
ORGANIZATION Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
-
REGULATORY Chuikyo Discusses ICER Evaluations for Drugs with Multiple Indications
August 23, 2018
-
REGULATORY Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
-
BUSINESS Mitsubishi Tanabe Going Digital to Shed Drug Discovery and Sales Outlays: President
August 21, 2018
-
BUSINESS I/O in Lung Cancer - 2: After MYSTIC Flop, AstraZeneca’s Imfinzi Makes Comeback with Stage III NSCLC Nod
August 20, 2018
-
REGULATORY MHLW Revving Up Biosimilar Drive with Educational Workshop for Healthcare Pros
August 17, 2018
-
REGULATORY Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
-
BUSINESS I/O in Lung Cancer - 1: US Merck Sweeping Frontline NSCLC Space with Keytruda
August 10, 2018
-
BUSINESS As Rituxan Biosimilar Enjoys Solid Start, Sandoz Japan Chief Says It’s Important to Be First to Market
August 9, 2018
-
BUSINESS Otsuka’s Half-Year Pharma Sales Up 4.1% on Global Brands
August 9, 2018
-
TRENDS Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
-
BUSINESS Sumitomo Dainippon Chief Rules Out Divestment of Cash-Cow LLPs
August 8, 2018
-
BUSINESS AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
-
BUSINESS Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
-
COMMENTARY There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…